Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bernard Gardner is active.

Publication


Featured researches published by Bernard Gardner.


Cancer | 1983

Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Bernard Fisher; Madeline Bauer; D. Lawrence Wickerham; Carol K. Redmond; Edwin R. Fisher; Anatolio B. Cruz; Roger S. Foster; Bernard Gardner; Harvey J. Lerner; Richard G. Margolese; Roger Poisson; Henry Shibata; Herbert Volk

The current findings completely affirm the validity of our original observations indicating the appropriateness of grouping primary breast cancer patients into those with negative, 1 to 3, or ≫4 positive nodes. Results, however, reveal that there is a risk in combining all patients with ≫4 positive nodes into a single group. Since there was a 25% greater disease‐free survival and an 18% greater survival in those with 4 to 6 than in those with ≫13 positive axillary nodes, such a unification may provide misleading information regarding patient prognosis, as well as the worth of a therapeutic regimen when compared with another from a putatively similar patient population. Of particular interest were findings relating the conditional probability, i.e., the hazard rate, of a treatment failure or death each year during the 5‐year period following operation to nodal involvement with tumor. Whereas the hazard rate for those with negative, or 1 to 3 positive nodes, was relatively low and constant, in those with ≫4 positive nodes the risk in the early years was much greater, but by the fifth year it was similar to that occurring when 1‐3 nodes were involved, and not much different from negative node patients. The same pattern existed whether 4 to 6 or ≫13 nodes were positive. When the current findings are considered relative to other factors with predictive import, it is concluded that nodal status still remains the primary prognostic discriminant.


Cancer | 1977

Comparison of radical mastectomy with alternative treatments for primary breast cancer: A first report of results from a prospective randomized clinical trial

Bernard Fisher; Eleanor D. Montague; Carol K. Redmond; Bruce Barton; Donna Borland; Edwin R. Fisher; Melvin Deutsch; George Schwarz; Richard G. Margolese; William L. Donegan; Herbert Volk; Carl Konvolinka; Bernard Gardner; Isidore Cohn; Gerson Lesnick; Anatolio B. Cruz; Walter Lawrence; Thomas F. Nealon; Harvey R. Butcher; Richard Lawton; other Nsabp investigators

In 1971, the National Surgical Adjuvant Breast Project (NSABP) implemented a prospective randomized clinical trial to compare the worth of alternative treatments with radical mastectomy in women with primary operable breast cancer. Information has been obtained from 1,665 patients eligible for follow‐up from 34 NSABP member institutions in Canada and the United States. Results from that trial, at present in its sixth year with patients on study for an average of 36 months, (26 to 62 months), fail to demonstrate an advantage for those who had a radical mastectomy. No significant difference in the treatment failure or survival has as yet been observed in clinically negative node patients who have been randomly managed by conventional radical mastectomy, total mastectomy with postoperative regional radiation or total mastectomy followed by axillary dissection of those patients who subsequently develop positive nodes. Similarly, there presently exists no difference between patients with clinically positive nodes treated by radical mastectomy or by total mastectomy followed by radiation. Of particular interest is the observation that based upon findings from radical mastectomy patients, there may be as many as 40% of patients having a total mastectomy who had histologically positive nodes unremoved, to date only 15% have developed positive nodes requiring an axillary dissection. The persistence of such a difference in incidence would have profound biological significance. The discovery that leaving behind positive axillary nodes has as yet not been influential in enhancing the incidence of distant metastases or the overall proportion of treatment failures and that a disproportionate number of treatment failures in the total mastectomy group occurred in those patients who subsequently required axillary dissection provides reinforcement to the view that positive axillary lymph nodes are not the predecessor of distant tumor spread but are a manifestation of disseminated disease.


Experimental Biology and Medicine | 1962

Urinary Calcium Excretion of Women with Breast Cancer during Post-Hypophysectomy Polyuria, Spontaneous Interphase and Vasopressin-Induced Antidiuresis.

Bernard Gardner; Gilbert S. Gordan; Joseph Witt

Summary (1) Urinary calcium excretion and creatinine clearance were measured in 8 patients before and after hypophysectomy for advanced breast cancer. (2) Mean creatinine clearance for the group was lower than in patients in an earlier stage of metastatic breast cancer. (3) No consistent changes in urinary calcium excretion could be correlated either with polyuria, spontaneous interphase, or vasopressin-induced reduction in urinary volume.


Cancer | 1962

Antitumor efficacy of prednisone and sodium liothyronine in advanced breast cancer

Bernard Gardner; Arthur N. Thomas; Gilbert S. Gordan


The Journal of Clinical Endocrinology and Metabolism | 1963

Calcium and Phosphate Metabolism in Patients with Disseminated Breast Cancer: Effect of Androgens and of Prednisone

Bernard Gardner; William P. Graham; Gilbert S. Gordan; Hans F. Loken; Arthur N. Thomas; James S. Teal


JAMA Internal Medicine | 1963

Secondary Hormonal Therapy of Disseminated Breast Cancer: Comparison of Hypophysectomy, Replacement Therapy, Estrogens, and Androgens

Joseph Witt; Bernard Gardner; Gilbert S. Gordan; William P. Graham; Arthur N. Thomas


The Journal of Clinical Endocrinology and Metabolism | 1962

Does Urinary Calcium Excretion Reflect Growth or Regression of Disseminated Breast Cancer

Bernard Gardner; Gilbert S. Gordan


Cancer | 1965

FAILURE OF OSTEOLYTIC AGENTS TO INDUCE SKELETAL METASTASES IN RATS WITH SARCOMA.

Bernard Gardner; Eugene Eisenberg; Dragutin M. Schmidt


JAMA Internal Medicine | 1964

Glomerular Filtration In Disseminated Breast Cancer

William P. Graham; Bernard Gardner; Gilbert S. Gordan


Springer US | 2009

In memoriam: Margaret Hay Edwards, MD, MPH September 15, 1914 to September 11, 1994

Kenneth B. Olson; Edward T. Krementz; W. P. Laird Myers; George J. Hill; Faan Josephine K. Craytor Rn; Susan J. Mellette; DSc Edwin A. Mirand PhD; Sol Silverman Jr. Ma; Facr Bernard S. Aron Md; Louis Bernard; Daisilee Berry; C. Michael Brooks EdD; Samuel Brown Jr. EdD; Norbert J. Burzynski Dds; Bernard Gardner; E. Milly L. Haagedoom Md; Erich Hirschberg; Harmon J. Eyre; Diane J. Fink; Harold B. Haley; Arthur I. Holleb; S. Benham Kahn; Barbara Lamb; Walter Lawrence; Henry M. Lemon; Mario G. Martinez Jr. Dmd; Condict Moore; Joseph F. O'Donnell; Mph Sidney J. Saltzstein Md; Charles D. Sherman

Collaboration


Dive into the Bernard Gardner's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anatolio B. Cruz

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar

Bernard Fisher

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Herbert Volk

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Joseph Witt

University of California

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge